Appointment marks expansion of Gyros Protein Technologies into Asia-Pacific region
Uppsala, Sweden, 11 April 2016: Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesis instrumentation and reagents, today announced the appointment of Peter Luk as Vice President, Asia-Pacific. Peter’s appointment marks a significant step in the expansion of the newly formed company into the Asia-Pacific region, in line with its strategy outlined at the time of merger.
Peter has over 25 years of life science business experience in Asia. Most recently he was General Manager of ProteinSimple, Asia, where he increased revenue in Asia more than four-fold over a period of five years. Prior to that Peter was Vice President, Asia-Pacific of Molecular Devices, and he has also held various management roles at PerkinElmer, Packard Biosciences and Bio-Rad Laboratories in the Asia-Pacific region. Peter holds an undergraduate degree in Biotechnology from the University of Leeds, UK, and a Master’s degree in Business Administration from the City University of Hong Kong.
Established in March 2016 by the merger of Gyros AB and Protein Technologies, Inc., Gyros Protein Technologies combines Gyros’ microfluidics, systems development and immunoassay expertise with Protein Technologies’ deep knowledge in developing and manufacturing instruments for peptide synthesis. The Company will provide customers an unrivaled range of sample prep, synthesis and bioanalytical tools for biotherapeutics discovery, development and bioprocessing. With an installed base of more than 1,000 instruments in biopharmaceutical and related markets, coupled with double digit revenue growth and EBITDA positive operations, the combined company is in a strong position to continue delivering innovative products to its customers.
Dan Calvo, CEO of Gyros Protein Technologies, commented: “We are delighted to welcome Peter to the Gyros Protein Technologies team. Asia-Pacific is experiencing tremendous growth in the biotherapeutic discovery, development and manufacturing markets that we serve. With Peter’s many years of experience and exceptional track record in building high value life science businesses in the Asia-Pacific market, we are confident he will be an invaluable asset as the company expands in the region.”
Pete Luk said: “I am excited to be joining Gyros Protein Technologies at this pivotal time. I look forward to be a part of a growing team, and to helping increase the Company’s reach in the Asia-Pacific region.”
Both Gyros and Protein Technologies introduced new platforms in 2015. Gyros launched Gyrolab xPlore™, an automated, nanoliter-scale, single CD immunoassay system, while Protein Technologies introduced the Prelude® X which incorporates novel, efficient heating and UV monitoring technology for economical, rapid synthesis of even the most difficult peptides.
Media contact:
Katie Odgaard
Zyme Communications
Tel: +44(0)7787 502 947
Email: Katie.odgaard@zymecommunications.com
About Gyros Protein Technologies (For more information please click here) Gyros Protein Technologies is a leading provider of sample preparation, synthesis and bioanalytical tools for biotherapeutics discovery, development and bioprocessing. Formed in March 2016 by the merger of Gyros AB and Protein Technologies, Inc., the Company combines Gyros’ microfluidics, systems development and immunoassay expertise with Protein Technologies’ deep knowledge in developing and manufacturing instruments for peptide synthesis.
With a large and growing installed base of instruments in the biopharmaceutical industry and related markets, Gyros Protein Technologies is leading its field in several key application areas in biotherapeutics, from research through Phase 4 clinical development and particularly in bioprocess. The Company holds a high growth, high margin product portfolio, including ~50% in recurring aftermarket consumables and service revenue, coupled with a reputation for exceptional customer service and support.
Gyros Protein Technologies has over 100 employees across the USA and Europe, and has development and manufacturing facilities in Uppsala, Sweden and Tucson, AZ, and a commercial site in Warren, NJ.
Current majority shareholders of both Gyros AB and Protein Technologies, Inc., which are the AP6 and Ampersand Capital Partners respectively, are the major shareholders in Gyros Protein Technologies AB.
